540 related articles for article (PubMed ID: 18703087)
1. The acute effects of NMDA antagonism: from the rodent to the human brain.
Gunduz-Bruce H
Brain Res Rev; 2009 May; 60(2):279-86. PubMed ID: 18703087
[TBL] [Abstract][Full Text] [Related]
2. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
3. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
4. The NMDA antagonist model for schizophrenia: promise and pitfalls.
Abi-Saab WM; D'Souza DC; Moghaddam B; Krystal JH
Pharmacopsychiatry; 1998 Jul; 31 Suppl 2():104-9. PubMed ID: 9754841
[TBL] [Abstract][Full Text] [Related]
5. Glutamatergic aspects of schizophrenia.
Tamminga C
Br J Psychiatry Suppl; 1999; (37):12-5. PubMed ID: 10211134
[TBL] [Abstract][Full Text] [Related]
6. Impaired glutamine metabolism in NMDA receptor hypofunction induced by MK801.
Brenner E; Kondziella D; Håberg A; Sonnewald U
J Neurochem; 2005 Sep; 94(6):1594-603. PubMed ID: 16045441
[TBL] [Abstract][Full Text] [Related]
7. NMDA receptors, cognition and schizophrenia--testing the validity of the NMDA receptor hypofunction hypothesis.
Gilmour G; Dix S; Fellini L; Gastambide F; Plath N; Steckler T; Talpos J; Tricklebank M
Neuropharmacology; 2012 Mar; 62(3):1401-12. PubMed ID: 21420987
[TBL] [Abstract][Full Text] [Related]
8. Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia?
Stefanovic A; Brandner B; Klaassen E; Cregg R; Nagaratnam M; Bromley LM; Das RK; Rossell SL; Morgan CJ; Curran HV
J Clin Psychopharmacol; 2009 Apr; 29(2):124-33. PubMed ID: 19512973
[TBL] [Abstract][Full Text] [Related]
9. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
10. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.
Bubeníková-Valesová V; Horácek J; Vrajová M; Höschl C
Neurosci Biobehav Rev; 2008 Jul; 32(5):1014-23. PubMed ID: 18471877
[TBL] [Abstract][Full Text] [Related]
11. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia.
Greene R
Hippocampus; 2001; 11(5):569-77. PubMed ID: 11732709
[TBL] [Abstract][Full Text] [Related]
12. The NMDA receptor complex: a long and winding road to therapeutics.
Wood PL
IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
[TBL] [Abstract][Full Text] [Related]
13. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
[TBL] [Abstract][Full Text] [Related]
14. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
Marek GJ; Behl B; Bespalov AY; Gross G; Lee Y; Schoemaker H
Mol Pharmacol; 2010 Mar; 77(3):317-26. PubMed ID: 19933774
[TBL] [Abstract][Full Text] [Related]
15. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
Large CH
J Psychopharmacol; 2007 May; 21(3):283-301. PubMed ID: 17591656
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
[TBL] [Abstract][Full Text] [Related]
17. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia.
du Bois TM; Huang XF
Brain Res Rev; 2007 Feb; 53(2):260-70. PubMed ID: 17014910
[TBL] [Abstract][Full Text] [Related]
18. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
Mouri A; Noda Y; Enomoto T; Nabeshima T
Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
[TBL] [Abstract][Full Text] [Related]
19. Glutamate as a therapeutic target in psychiatric disorders.
Javitt DC
Mol Psychiatry; 2004 Nov; 9(11):984-97, 979. PubMed ID: 15278097
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
